Comparative Efficacy of Combined Rocuronium -Atracurium in Patients Undergoing Day care abdominal Laparoscopic Surgery: A prospective, three arm, Randomized Controlled Study - nil

Start Date13 Jan 2026

Sponsor / Collaborator-

CTRI/2024/10/075144

/ Not yet recruitingNot ApplicableIIT

A prospective randomized study in comparing intubating conditions with and without priming with rocuronium - NIL

Start Date10 Sep 2025

Sponsor / Collaborator-

CTRI/2025/04/085595

/ Not yet recruitingPhase 2/3IIT

Rocuronium Bromide versus Succinylcholine Chloride for rapid sequence induction and intubation in emergency cases- a prospective randomized clinical study - Nil

Start Date15 May 2025

Sponsor / Collaborator-

100 Clinical Results associated with Rocuronium Bromide

100 Translational Medicine associated with Rocuronium Bromide

100 Patents (Medical) associated with Rocuronium Bromide

3,820

Literatures (Medical) associated with Rocuronium Bromide

31 Dec 2025·JOURNAL OF INVESTIGATIVE SURGERY

The Effect and Safety of Dexmedetomidine Administration on Mother and Foetus/Neonates During General Anaesthesia in Caesarean Section: A Randomised Controlled Trial

Article

Author: Yan, Dong ; Yu, Zhiqiang ; Duan, Fangqi ; Zhang, Li ; Wang, Zhuangzhuang ; Zhao, Qi ; Zhang, Minyu ; Li, Qian ; Liu, Yan

PURPOSE:

This study aimed to assess the safety of dexmedetomidine administration to mothers, fetuses, and neonates during general anesthesia in cesarean section (CS).

PATIENTS AND METHODS:

A total of 60 parturients scheduled for elective CS under general anesthesia were randomly divided into anesthesia in groups (DEX1 and DEX2) and control (C) groups. Groups DEX1 and DEX2 were induced with dexmedetomidine (induction, 0.4 µg/kg; maintenance, 0.4 µg/kg·h) and dexmedetomidine (induction, 0.6 µg/kg; maintenance, 0.6 µg/kg·h), respectively, until birth. Equivalent volumes of normal saline were administered in group C. Anesthesia was induced with propofol and rocuronium in all groups. The mean arterial blood pressure (MAP) and heart rate (HR) of parturients were monitored and recorded; fetal HR was monitored using color doppler ultrasound. The blood gas analysis from the umbilical artery (UA) and umbilical vein (UV), along with the HR, Apgar score and Neurologic Adaptive Capacity Scores (NACS) of neonates, were recorded.

RESULTS:

Maternal MAP at intubation/skin incision, maternal HR at intubation/skin incision and delivery were significantly lower in groups DEX1 and DEX2 than in group C, no significant differences were observed between groups DEX1 and DEX2. No significant differences were observed in fetal HR, UA and UV blood gas analyses, Apgar score and NACS of neonates in the three groups.

CONCLUSION:

Intravenous 0.4 or 0.6 µg/kg doses of dexmedetomidine with propofol for general anesthesia in CS is beneficial for inhibiting the maternal stress response induced by intubation/skin incision and delivery without significant adverse effects on fetuses or neonates. Our findings suggest that dexmedetomidine is safe for mothers, fetuses, and neonates in obstetric general anesthesia.

01 Jun 2025·ANESTHESIOLOGY

Neuromuscular Blockade and Antagonism in Patients with Renal Impairment: A Multicenter Retrospective Cross-sectional Study

Article

Author: Mentz, Graciela ; Mhyre, Jill M. ; Colquhoun, Douglas A. ; Zhao, Xinyi ; Campbell, Davis L. ; Kumar, Sathish ; Elkhateb, Rania ; El Sharawi, Nadir ; Kheterpal, Sachin

Background::

Current practice guidelines do not address the use of neuromuscular blocking and antagonism agents in patients with renal impairment. The U.S. Food and Drug Administration (Silver Spring, Maryland) label for sugammadex advises against use in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 ml/min). Using a multicenter electronic health record registry, the authors sought to understand the modern use of neuromuscular blockade and antagonism agents in patients with significant renal impairment (eGFR less than 60 ml/min).

Methods::

Data were obtained from the Multicenter Perioperative Outcomes Group (MPOG) registry for adult patients (older than 18 yr) with an eGFR less than 60 ml/min, based on most recent serum creatinine, receiving general anesthesia for a nonrenal transplant procedure with an endotracheal tube between January 1, 2016, and July 31, 2022. Patients were classified into three mutually exclusive blockade and reversal strategies: rocuronium–sugammadex, cisatracurium–neostigmine, and rocuronium–neostigmine. Adjusted incidence of each blockade reversal strategy was established by a multinomial mixed effects model. The contribution of institution, anesthesiologist, and patient or case factors to variation in strategy choice was assessed by multilevel mixed effects models.

Results::

In 243,944 cases across 5,133 anesthesiologists and 48 institutions, adjusted use of rocuronium–sugammadex increased from 4.4 to 95.2%, rocuronium–neostigmine decreased from 84.7 to 4.3%, and cisatracurium–neostigmine decreased from 10.9 to 0.5%. In patients with an eGFR less than 15 ml/min, rocuronium–sugammadex use increased from 0.5 to 86.9%. Of the variation in choice of rocuronium–sugammadex versus cisatracurium–neostigmine, 30.1% was attributed to the institution, 22.7% to the attending anesthesiologist, and 47.2% to patient/case factors or was unexplained. The adjusted median odds ratio for this choice was 2.5 for clinicians and 3.1 for institutions.

Conclusion::

Rocuronium–sugammadex is the primary neuromuscular blockade–antagonism strategy for patients with moderate and severe renal impairment. Variation in choice is significantly impacted by the institution and attending anesthesiologist providing care.

01 Jun 2025·BRITISH JOURNAL OF ANAESTHESIA

Developing novel drugs to reverse neuromuscular block: do we need them?

Review

Author: Hunter, Jennifer M ; Blobner, Manfred

In the last 5 yr, rocuronium followed by reversal with sugammadex has become the most common combination of neuromuscular blocking drug and neuromuscular block antagonist in use during anaesthesia in the developed world. Despite a low incidence of side-effects from this drug combination, research continues on the development of new reversal agents. This includes development of new gamma cyclodextrins such as adamgammadex, and unrelated compounds such as calabadion 2 and Pillar[6]MaxQ, that not only sequestrate rocuronium, but also opioids such as fentanyl. The reasons for such work are questioned with the acknowledgement that, as in all areas of anaesthetic practice, the search for perfect drugs continues despite the limited clinical demand.

News (Medical) associated with Rocuronium Bromide

03 Dec 2024

·www.prnewswire.com

75% of Hospitals Face Medication Shortages - Germfree and On Demand Pharmaceuticals Partner to Deliver Localized Production Solutions

Partners working to expand program after successful six-month pilot study at North Mississippi Medical Center, which enabled production of 12,000 doses of multiple drugs in limited supply ORMOND BEACH, Fla., Dec. 3, 2024 /PRNewswire/ -- Germfree Laboratories, On Demand Pharmaceuticals (ODP), and North Mississippi Medical Center-Tupelo (NMMC) have teamed up to address the global drug shortage crisis with a groundbreaking point-of-care medicine production solution. The expanding partnership aims to bring agile production of essential medicines closer to the point of care across the country and globally, ensuring a reliable supply of life-saving drugs. Continue Reading Pharmacy staff monitoring pharmacy operations digitally With more than 75% of U.S. hospitals facing medication shortages and millions of people in low- and middle-income countries lacking access to critical medicines, the need for localized, flexible production is urgent. By combining Germfree's mobile cleanroom technology with ODP's Pharmacy on Demand platform, this collaboration empowers healthcare providers to produce high-quality medications on site, reducing reliance on fragile global supply chains. The partnership builds on a six-month pilot study that leveraged ODP's platform technology and Germfree's mobile cleanroom capability to produce syringes of common shortage medicines at NMMC, including lidocaine, rocuronium, and potassium chloride. This real-world pilot met all regulatory requirements, leveraged a state-of-the art quality management approach, and demonstrated a novel, agile compounding capability for drugs on shortage. It resulted in patients being treated with high-quality medicines that were made on-demand and on-site. "We're not just filling gaps in the supply chain, we're redefining it," said Kevin Kyle, CEO of Germfree. "With On Demand Pharma, we are enabling healthcare providers to meet patient needs faster and more reliably, whether in urban centers or rural areas. This partnership also demonstrates our commitment to using cutting-edge technologies to improve the way hospital pharmacies respond to the needs of their patients, with more to come." Matt Pietras, CEO of On Demand Pharmaceuticals, added, "This collaboration with Germfree provides us with the high-quality modular infrastructure needed to provide our Medication-as-a-Service (MaaS) where patients and healthcare providers need it most." The innovative model will allow hospitals like NMMC to produce critical medications locally, improving access for patients and ensuring continuity of care even during global supply disruptions. "Our pilot work completed through this collaboration has proven these new capabilities for on-site compounded medications are able to help us better serve our communities in a timelier manner," said Wes Pitts, System Director of Pharmacy at North Mississippi Health Services, which includes NMMC in Tupelo. "In our pilot program, we were able to successfully compound approximately 12,000 doses of shortage medications starting in December 2023 following regulations from the Board of Pharmacy." "We are on the cusp of expanding distributed medicine production through our network while creating a new paradigm," said John Lewin, Chief Medical Officer at ODP. "I envision a future where pharmacists take a leading role in medicine production – both today and as personalized medicine becomes the standard at the point of care." The collaboration between Germfree and On Demand Pharmaceuticals is set to transform the future of medicine accessibility by providing healthcare providers with the tools to produce medications on demand, whenever and wherever they are needed. About Germfree Laboratories: Germfree Laboratories is a global leader in cleanroom and critical environment technologies, specializing in providing innovative solutions for biopharmaceutical, healthcare, and research sectors. Learn more at . About On Demand Pharmaceuticals: On Demand Pharmaceuticals (ODP) is revolutionizing pharmaceutical access with its Pharmacy on Demand platform, offering agile, on-site production of medications. ODP is committed to overcoming industry barriers and ensuring high-quality medicines are accessible to all. Learn more at . About North Mississippi Medical Center: North Mississippi Medical Center (NMMC) is one of the largest non-metropolitan hospitals in the U.S., providing comprehensive medical services to a growing community. NMMC is committed to innovation in healthcare delivery to ensure high-quality, accessible care for its patients. For more information, visit . SOURCE Germfree Laboratories LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

27 Feb 2024

·www.biospace.com

Merck’s Bridion Could Face Generic Pressure from Hikma Ahead of Patent Expiry Date

Pictured: Merck research laboratories in California/iStock, hapabapa Merck in an SEC filing disclosed on Monday that Hikma Pharmaceuticals U.S. is seeking the FDA’s approval for its generic version of the muscle relaxant reversal injection Bridion (sugammadex) prior to the drug’s patent expiration. Hikma notified Merck of its intention on Feb. 5, 2024, according to the SEC filing. The British pharma is making its regulatory request under the Hatch-Waxman Act—also known as the Drug Price Competition and Patent Term Restoration Act of 1984—which established the approval pathway for generics. Specifically, Hikma is seeking approval for its Bridion copycat through a Paragraph IV Patent Certification letter, which according to the FDA’s website allows the approval of generics given that the patent for its reference product is “invalid, unenforceable, or will not be infringed by the generic product.” Under the Paragraph IV process, Merck has 45 days from being notified of the patent challenge to infringement suit against Hikma. While the court resolves the complaint, the FDA’s approval for the generic product is generally postponed for 30 months, unless the patent expires or a judge decides against the patent holder before then. Merck is “currently considering its options,” according to its SEC filing. Bridion is a modified gamma cyclodextrin that works by diffusing through the patient’s plasma and capturing the neuromuscular blocking agents rocuronium and vecuronium. The injectable drug first won the FDA’s approval in 2015 for use in adults undergoing surgery. It carries warnings against anaphylaxis and bradycardia, while its most common adverse events include vomiting, pain and nausea. The drug is one of Merck’s top-selling assets—and is still showing signs of growth. In 2023, Bridion brought in a little more than $1.84 billion, an increase from nearly $1.69 billion in revenue in 2022 and $1.53 billion in 2021, according to the SEC filing. In June 2023, the U.S. District Court for the District of New Jersey ruled in favor of Merck, finding that the company had correctly calculated its Patent Term Extension duration for Bridion. The court ruling protects Bridion from generic competition in the U.S. through at least January 2026. Bridion’s protections have already expired in the EU, in Japan and in China. At the time, Merck General Counsel Jennifer Zachary in a statement said that the decision will ultimately allow the company “to continue investing in research and development,” bringing new and innovative treatments to patients with unmet medical needs. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Patent InfringementDrug ApprovalPatent Expiration

27 Feb 2024

·www.biospace.com

Merck’s Bridion Could Face Generic Pressure from Hikma Ahead of Patent Expiry Date

Merck Research Laboratories in South San Francisco, California iStock, hapabapa Despite a patent extension, Merck’s muscle relaxant reversal injection is now facing potential generic competition from Hikma Pharmaceuticals, which is seeking the FDA’s approval for a copycat version. Pictured: Merck research laboratories in California/iStock, hapabapa Merck in an SEC filing disclosed on Monday that Hikma Pharmaceuticals U.S. is seeking the FDA’s approval for its generic version of the muscle relaxant reversal injection Bridion (sugammadex) prior to the drug’s patent expiration. Hikma notified Merck of its intention on Feb. 5, 2024, according to the SEC filing. The British pharma is making its regulatory request under the Hatch-Waxman Act —also known as the Drug Price Competition and Patent Term Restoration Act of 1984—which established the approval pathway for generics. Specifically, Hikma is seeking approval for its Bridion copycat through a Paragraph IV Patent Certification letter, which according to the FDA’s website allows the approval of generics given that the patent for its reference product is “invalid, unenforceable, or will not be infringed by the generic product.” Under the Paragraph IV process, Merck has 45 days from being notified of the patent challenge to infringement suit against Hikma. While the court resolves the complaint, the FDA’s approval for the generic product is generally postponed for 30 months, unless the patent expires or a judge decides against the patent holder before then. Merck is “currently considering its options,” according to its SEC filing. Bridion is a modified gamma cyclodextrin that works by diffusing through the patient’s plasma and capturing the neuromuscular blocking agents rocuronium and vecuronium. The injectable drug first won the FDA’s approval in 2015 for use in adults undergoing surgery. It carries warnings against anaphylaxis and bradycardia, while its most common adverse events include vomiting, pain and nausea. The drug is one of Merck’s top-selling assets—and is still showing signs of growth. In 2023, Bridion brought in a little more than $1.84 billion, an increase from nearly $1.69 billion in revenue in 2022 and $1.53 billion in 2021, according to the SEC filing. In June 2023, the U.S. District Court for the District of New Jersey ruled in favor of Merck , finding that the company had correctly calculated its Patent Term Extension duration for Bridion. The court ruling protects Bridion from generic competition in the U.S. through at least January 2026. Bridion’s protections have already expired in the EU, in Japan and in China. At the time, Merck General Counsel Jennifer Zachary in a statement said that the decision will ultimately allow the company “to continue investing in research and development,” bringing new and innovative treatments to patients with unmet medical needs. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com .

Drug ApprovalPatent InfringementPatent Expiration

100 Deals associated with Rocuronium Bromide

External Link

KEGG	Wiki	ATC	Drug Bank
D00765	Rocuronium Bromide	M03AC09	DBSALT000575

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperemesis Gravidarum	China	Organon NV	07 Oct 2000
Anesthesia	United States	Organon USA, Inc.	17 Mar 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Insufficiency	Phase 3	-	Merck Sharp & Dohme Corp.	01 Apr 2008
Voice Disorders	Phase 1	Canada	Merck Sharp & Dohme Corp.	01 Jul 2017
Ventilator-Induced Lung Injury	Clinical	United States	Merck Sharp & Dohme Corp.	01 Jan 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02631135 (CTgov)	Phase 4	-	40	Propofol+Rocuronium+Remifentanil (Group 1 (TIVA))	lzhowzdzqa(ydvhxtfwww) = tolfphrdcw qgedvyezrv (buqirigvod, 1.31) View more	-	17 May 2024
				Dexmedetomidine+Propofol+Rocuronium+Remifentanil (Group 2 (TIVA+D))	lzhowzdzqa(ydvhxtfwww) = rrvzllacym qgedvyezrv (buqirigvod, 1.19) View more
NCT04512313 \| NCT03857750 (Pubmed)	Not Applicable	Anesthesia	50	Rocuronium 0.6 mg/kg	zdmcwzjkod(wjrwcwpmzl) = yubptmnsij phalwlnvlr (pbjzzpxpkk, 10 - 33)	-	13 May 2024
				Rocuronium 0.9 mg/kg	zdmcwzjkod(wjrwcwpmzl) = uemyrhuyop phalwlnvlr (pbjzzpxpkk, 95% CI not provided)
NCT05343702 (Pubmed \| Rev Assoc Med Bras (1992))	Not Applicable	-	52	rocuronium (Standard rapid sequence intubation)	nutrpgajjq(eqbxebijsq) = uyztcxiojv yeegsnsbet (ixaeuujbgd ) View more	Positive	01 Jan 2024
				Rocuronium priming	nutrpgajjq(eqbxebijsq) = ugcrfcduxp yeegsnsbet (ixaeuujbgd ) View more
NCT03939923 (CTgov)	Phase 4	Coronary Artery Disease	84	Glycopyrrolate+Neostigmine+Rocuronium (Neostigmine/Glycopyrrolate)	rcpgcfuqsd(lmvgqxudit) = hsgdoajuhy vilamthcic (mjfrukwomp, 5.9) View more	-	22 Dec 2023
				sugammadex+Rocuronium (Sugammadex)	rcpgcfuqsd(lmvgqxudit) = qicmvsmhgo vilamthcic (mjfrukwomp, 4.7) View more
NCT03904550 (CTgov)	Phase 2	Renal Insufficiency	49	Cisatracurium+Neostigmine (Cisatracurium + Neostigmine)	agvhoyhuqj(gnthvtdgkx) = dqjodofuty szuwgpfyef (fwdbiftajb, 6.1) View more	-	03 Jul 2023
				sugammadex+Rocuronium (Rocuronium + Sugammadex)	agvhoyhuqj(gnthvtdgkx) = ytuntdvuwy szuwgpfyef (fwdbiftajb, 1.6) View more
NCT03958201 (CTgov)	Phase 4	Paralysis	200	Rocuronium	pqmaerauhg = qrkkbdtmbc cmoasuhybu (zzrxrrybds, yofrfiajyn - rqucocfjrh) View more	-	02 Nov 2022
Pubmed \| Eur J Anaesthesiol	Not Applicable	Myasthenia Gravis	1,143	Rocuronium reversed with sugammadex	ooavhvwhuv(lctylkuqby) = jvqdznqwsf warxvbrqdw (vgbynundii )	Positive	01 Aug 2021
NCT04287426 (Pubmed \| Acta Anaesthesiol Scand)	Phase 4	-	78	Rocuronium 0.6 mg kg-1	yyntgzstgl(kumblkagan) = vdasxlzket ttxclrlqxi (hgazdnfofb )	-	26 Jul 2021
				Remifentanil 2 µg kg-1	yyntgzstgl(kumblkagan) = jfdrfayvok ttxclrlqxi (hgazdnfofb )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rocuronium Bromide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation